105 results on '"Antonucci, L"'
Search Results
2. Nonlinear beam shaper for femtosecond laser pulses, from Gaussian to flat-top profile
- Author
-
Mercier, B., Rousseau, J.P., Jullien, A., and Antonucci, L.
- Published
- 2010
- Full Text
- View/download PDF
3. Nonlinear spectral cleaning of few-cycle pulses via cross-polarized wave (XPW) generation
- Author
-
Jullien, A., Durfee, C. G., Trisorio, A., Canova, L., Rousseau, J.-P., Mercier, B., Antonucci, L., Chériaux, G., Albert, O., and Lopez-Martens, R.
- Published
- 2009
- Full Text
- View/download PDF
4. Spectral broadening and pulse duration reduction during cross-polarized wave generation: influence of the quadratic spectral phase
- Author
-
Jullien, A., Canova, L., Albert, O., Boschetto, D., Antonucci, L., Cha, Y.-H., Rousseau, J.P., Chaudet, P., Chériaux, G., Etchepare, J., Kourtev, S., Minkovski, N., and Saltiel, S.M.
- Published
- 2007
- Full Text
- View/download PDF
5. Holographic interferometry for the structural diagnostics of UV laser ablation of polymer substrates
- Author
-
Bonarou, A., Antonucci, L., Tornari, V., Georgiou, S., and Fotakis, C.
- Published
- 2001
- Full Text
- View/download PDF
6. P.307 Resting state MRI functional connectivity and negative symptoms in subjects with schizophrenia
- Author
-
Perrottelli, A., Giordano, G.M., Fazio, L., Blasi, G., Pergola, G., Sangiuliano, M., Antonucci, L., Pezzella, P., Mucci, A., Galderisi, S., Bertolino, A., and Maj, M.
- Published
- 2021
- Full Text
- View/download PDF
7. P.507 Machine learning classification of first-episode psychosis using cortical thickness: a large multicenter magnetic resonance imaging study
- Author
-
Pigoni, A., Squarcina, L., Dwyer, D., Borgwardt, S., Crespo-Facorro, B., Dazzan, P., Smesny, S., Spaniel, F., Spalletta, G., Sanfelici, R., Antonucci, L., Reuf, A., Oeztuerk, O., Schmidt, A., Ciufolini, S., Harrisberger, F., Langbein, K., Gussew, A., Reichenbach, J., Zaytseva, Y., Piras, F., Bellani, M., Ruggeri, M., Lasalvia, A., Tordesillas-Gutiérrez, D., Ortiz, V., Koutsouleris, N., and Brambilla, P.
- Published
- 2020
- Full Text
- View/download PDF
8. Copper levels contribute together with the myc oncogene to liver transformation
- Author
-
Porcu, C., Antonucci, L., Barbaro, B., and Balsano, C.
- Published
- 2017
- Full Text
- View/download PDF
9. Involvement of copper in the liver tumorigenesis
- Author
-
Porcu, C., Antonucci, L., Barbaro, B., Arciello, M., Viscomi, C., and Balsano, C.
- Published
- 2016
- Full Text
- View/download PDF
10. High Mobility Group Box 1 (HMGB1) and neutrophils an unexpected role in non-alcoholic fatty liver disease: Inhibition of T cell activation and proliferation
- Author
-
Antonucci, L., Picozza, M., Renzi, A., Gaudio, E., and Balsano, C.
- Published
- 2016
- Full Text
- View/download PDF
11. FRI-238 - An Unexpected Role of High Mobility Group Box 1 (HMGB1) and Neutrophils in Non-Alcoholic Fatty Liver Disease: Inhibition of T Cell Activation and Proliferation
- Author
-
Antonucci, L., Picozza, M., Renzi, A., Gaudio, E., and Balsano, C.
- Published
- 2016
- Full Text
- View/download PDF
12. Relationship between inflammatory mediators and frequency of the innate immune cells in patients with non-alcoholic fatty liver disease
- Author
-
Maggio, R., Antonucci, L., Viscomi, C., Costantini, S., Castello, G., and Balsano, C.
- Published
- 2015
- Full Text
- View/download PDF
13. PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress.
- Author
-
Mazzà, D, Infante, P, Colicchia, V, Greco, A, Alfonsi, R, Siler, M, Antonucci, L, Po, A, De Smaele, E, Ferretti, E, Capalbo, C, Bellavia, D, Canettieri, G, Giannini, G, Screpanti, I, Gulino, A, and Di Marcotullio, L
- Subjects
HEDGEHOG signaling proteins ,UBIQUITIN ligases ,GENETIC toxicology ,CANCER ,MEDULLOBLASTOMA ,DNA damage - Abstract
The Hedgehog (Hh) signaling regulates tissue development, and its aberrant activation is a leading cause of malignancies, including medulloblastoma (Mb). Hh-dependent tumorigenesis often occurs in synergy with other mechanisms, such as loss of p53, the master regulator of the DNA damage response. To date, little is known about mechanisms connecting DNA-damaging events to morphogen-dependent processes. Here, we show that genotoxic stress triggers a cascade of signals, culminating with inhibition of the activity of Gli1, the final transcriptional effector of Hh signaling. This inhibition is dependent on the p53-mediated elevation of the acetyltransferase p300/CBP-associated factor (PCAF). Notably, we identify PCAF as a novel E3 ubiquitin ligase of Gli1. Indeed PCAF, but not a mutant with a deletion of its ubiquitination domain, represses Hh signaling in response to DNA damage by promoting Gli1 ubiquitination and its proteasome-dependent degradation. Restoring Gli1 levels rescues the growth arrest and apoptosis effect triggered by genotoxic drugs. Consistently, DNA-damaging agents fail to inhibit Gli1 activity in the absence of either p53 or PCAF. Finally, Mb samples from p53-null mice display low levels of PCAF and upregulation of Gli1 in vivo, suggesting PCAF as potential therapeutic target in Hh-dependent tumors. Together, our data define a mechanism of inactivation of a morphogenic signaling in response to genotoxic stress and unveil a p53/PCAF/Gli1 circuitry centered on PCAF that limits Gli1-enhanced mitogenic and prosurvival response. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. 14-fs high temporal quality injector for ultra-high intensity laser
- Author
-
Antonucci, L., Rousseau, J.P., Jullien, A., Mercier, B., Laude, V., and Cheriaux, G.
- Subjects
- *
LASERS , *LIGHT amplifiers , *GAUSSIAN beams , *REFLECTANCE , *NONLINEAR optics , *SPECTRUM analysis - Abstract
Abstract: We present a chirped pulse amplification (CPA) Ti:Sa laser generating sub-15fs pulses with expected high temporal quality. Gain-narrowing in the pre-amplifier is balanced by a variable spectral reflectivity mirror and by a fine adaptation of the saturation conditions. A crossed polarized wave generation (XPW) filter is introduced to enhance the contrast, reduce the pulse duration and improve the spectral quality. The pulses are generated at 10Hz repetition rate, with pulse energy of 110μJ and very clean Gaussian spectrum. The temporal contrast is evaluated by a measurement before the XPW filter and calculations of the enhancement by the filter. The potential temporal incoherent contrast is 1012 and the coherent contrast 1010. The performance of the system makes it suitable as an injector for petawatt lasers operating in the double-CPA scheme. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
15. Mechanism and dynamics of fatty acid photodecarboxylase.
- Author
-
Sorigué, D., Hadjidemetriou, K., Blangy, S., Gotthard, G., Bonvalet, A., Coquelle, N., Samire, P., Aleksandrov, A., Antonucci, L., Benachir, A., Boutet, S., Byrdin, M., Cammarata, M., Carbajo, S., Cuiné, S., Doak, R. B., Foucar, L., Gorel, A., Grünbein, M., and Hartmann, E.
- Published
- 2021
16. Dual Inhibition of Dipeptidyl Peptidase IV and Neutral Endopeptidase 24.11 Decreases the Metabolic Clearance Rate of Active GLP-1 Over DPPIV Inhibition Alone in the Female Zucker Diabetic Fatty (ZDF) Rat.
- Author
-
Farb, Thomas, Mika, A., Droz, B., Antonucci, L., Dickinson, B., Adler, A., Voorbach, M., Beno, D., Backes, B., Von Geldern, T., Trevillyan, J, Jacobson, P., and Brune, M.
- Subjects
CD26 antigen ,METABOLIC clearance rate ,ENDOPEPTIDASES ,GLUCAGON-like peptide 1 ,TREATMENT of diabetes ,ENZYME inhibitors ,HYPOGLYCEMIC agents - Abstract
Preserving the active form of the incretin hormone GLP-1 by inhibiting dipeptidyl peptidase IV (DPPIV) has been shown to be an effective anti-diabetic therapy. Combining DPPIV inhibitors with inhibitors of other proteases known to degrade active GLP-1, such as neutral endopeptidase 24.11 (NEP) may enhance the therapeutic effect. In this study, we evaluated the effects of DPPIV and NEP inhibition, alone and in combination, on GLP-1 clearance in conscious female ZDF rats. Two separate 30-minute iv infusions of GLP-l(7-36; 3 pmol/kg/min) were performed one hour apart. Thirty minutes prior to the second infusion, rats were dosed orally with either 1) a selective DPPIV inhibitor (A-899301; Ki = 1.3 nM; 3 mg/kg), 2) the selective NEP inhibitor candoxatril (CAN; Ki = 1 nM; 100 mg/kg), 3) their combination or 4) vehicle. Arterial blood samples were taken for subsequent determination of active GLP-1 in plasma at regular intervals from 30 min before the first infusion until 60 minutes after the second infusion. The first GLP-1 infusion caused an approximate 2-fold increase in plasma active GLP-1 over the pre-infusion baseline levels of 20-40 pM. No significant change in area under the GLP-1 curve (AUC) was observed from the first to the second infusion in vehicle (715±117 vs 1044±207 pM*min) or CAN (877±359 vs 1257±450 pM*min) treated rats. In contrast, A-899301 caused a 4-fold increase in AUC (807±186 vs 3387±304 pM*min) while the combination increased AUC 8-fold (761±142 vs 6329±613 pM*min), a further 2-fold increase over A899301 alone. In summary, DPPIV inhibition alone caused an increase in AUC (decrease in GLP-1 clearance) that was further augmented by co-inhibition of NEP. Such potentiation of active GLP-1 by DPPIV/NEP dual inhibition may result in additional anti-diabetic benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2007
17. Neurocognitive dysfunction in adolescents with recent onset major depressive disorder: a cross-sectional comparative study.
- Author
-
Bienek O, Allott K, Antonucci L, Bertolino A, Bonivento C, Borgwardt S, Brambilla P, Chisholm K, Dannlowski U, Lichtenstein TK, Kambeitz J, Kambeitz-Ilankovic L, Koutsouleris N, Lencer R, Griffiths SL, Maggioni E, Meisenzahl E, Pantelis C, Rosen M, Ruhrmann S, Salokangas RKR, Stainton A, Surmann M, Upthegrove R, Wenzel J, Wood SJ, Romer G, and Müller JM
- Abstract
The aim of this study was to examine the neurocognitive deficits associated with the first episode of major depressive disorder (recent onset depression, ROD) in adolescents as compared to adult patients. Cross-sectional neurocognitive data from the baseline assessments of the PRONIA study with N = 650 (55.31% females) were analyzed. Based on a principal component analysis of eleven neurocognitive tests, we constructed an overall neurocognitive performance (NP) score. We examined mean score differences in NP between the groups of healthy controls (HC) and ROD and between adolescents (15-21 years) and adults (22-40 years) within a GLM approach. This accounts for unbalanced data with focus on interaction effects while controlling for effects of medication and educational years. Our results show lower NP for the ROD as compared to the HC group (d = - 0.29, p = .046) and lower NP for the adolescent group as compared to the adult group (d = - 0.29; p < .039). There was no interaction between these two group effects (F = 1.11; p = .29). Our findings suggest that the detrimental effect of ROD on neurocognitive functioning is comparable in adolescent and adult patients, since lower scores in adolescent patients are explained by effects of age and education. Neurocognitive impairment is an under addressed issue in clinical treatment guidelines for adolescent MDD. We suggest efficient monitoring in clinical practice by using an aggregate of the Digit Symbol Substitution Test and the Trail Making Test B, which highly correlated with the overall score of NP (r = 0.82)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
- Author
-
D'Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, Garzia I, Antonucci L, Micarelli E, Venafra V, Gogov S, Capone A, Runswick S, Martin-Liberal J, Calvo E, Moreno V, Symeonides SN, Scarselli E, and Bechter O
- Subjects
- Humans, Female, Middle Aged, Male, Melanoma therapy, Melanoma immunology, Aged, Vaccination methods, T-Lymphocytes immunology, Adult, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines immunology, Cancer Vaccines administration & dosage, Antigens, Neoplasm immunology, Antigens, Neoplasm genetics, Genetic Vectors genetics, Genetic Vectors administration & dosage, Precision Medicine methods, Adenoviridae genetics, Adenoviridae immunology
- Abstract
Purpose: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is a vector-based personalized vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara. Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-naïve patients with metastatic melanoma (NCT04990479)., Patients and Methods: The feasibility of this approach was demonstrated by producing, releasing, and administering to 6 patients 11 of 12 vaccines within 8 weeks from biopsy collection to GAd20 administration., Results: The regimen was safe, with no treatment-related serious adverse events observed and mild vaccine-related reactions. Vaccine immunogenicity was demonstrated in all evaluable patients receiving the prime/boost regimen, with detection of robust neoantigen-specific immune responses to multiple neoantigens comprising both CD4 and CD8 T cells. Expansion and diversification of vaccine-induced T-cell receptor (TCR) clonotypes was observed in the posttreatment biopsies of patients with clinical response, providing evidence of tumor infiltration by vaccine-induced neoantigen-specific T cells., Conclusions: These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor-reactive T cells to empower a diverse, potent, and durable antitumor immune response. Finally, a gene signature indicative of the reduced presence of activated T cells together with very poor expression of the antigen-processing machinery genes has been identified in pretreatment biopsies as a potential biomarker of resistance to the treatment., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
19. Childhood-onset IgA nephropathy: is long-term recovery possible?
- Author
-
Antonucci L, Fuiano L, Gargiulo A, Gianviti A, Onetti Muda A, Diomedi Camassei F, Vivarelli M, and Emma F
- Subjects
- Humans, Child, Child, Preschool, Adolescent, Retrospective Studies, Glomerular Filtration Rate, Kidney Glomerulus pathology, Proteinuria pathology, Kidney pathology, Glomerulonephritis, IGA drug therapy, Glomerulosclerosis, Focal Segmental pathology
- Abstract
Background: IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. While studies have primarily focused on identifying risk factors for disease progression, very few data exist on the likelihood of achieving complete recovery from the disease., Methods: We conducted a single-center retrospective study on all consecutive patients with biopsy-proven IgAN diagnosed between 1986 and 2018 in our pediatric center. Biopsies were classified according to the MEST-C Oxford classification score. "Complete clinical remission" was defined as the absence of proteinuria, hematuria, and hypertension in patients with normal kidney function who had been off therapy for more than 2 years., Results: Overall, 153 patients with age at onset of 10.6 ± 4 years were enrolled in the study. Of these, 41 achieved "complete clinical remission." The estimated probability of complete clinical remission at 10 years was 43% (95%CI 33-54). However, seven patients relapsed within 10 years. Multivariable analysis showed that higher age at onset (HR 0.89, 95%CI 0.80-0.98, p = 0.017) and segmental glomerulosclerosis lesions (HR 0.28, 95%CI 0.10-0.79, p = 0.017) decreased significantly the chances of achieving complete clinical remission. Immunosuppressive therapy was not significantly associated with clinical outcomes., Conclusions: Approximately one-third of patients with pediatric-onset IgAN achieve prolonged remission, in particular, very young children at disease onset without sclerotic glomerular lesions. Longer term follow-up is needed to assess if these patients have achieved permanent remission., (© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)
- Published
- 2024
- Full Text
- View/download PDF
20. Catalytic Mechanism of Fatty Acid Photodecarboxylase: On the Detection and Stability of the Initial Carbonyloxy Radical Intermediate.
- Author
-
Aleksandrov A, Bonvalet A, Müller P, Sorigué D, Beisson F, Antonucci L, Solinas X, Joffre M, and Vos MH
- Abstract
In fatty acid photodecarboxylase (FAP), light-induced formation of the primary radical product RCOO⋅ from fatty acid RCOO
- occurs in 300 ps, upon which CO2 is released quasi-immediately. Based on the hypothesis that aliphatic RCOO⋅ (spectroscopically uncharacterized because unstable) absorbs in the red similarly to aromatic carbonyloxy radicals such as 2,6-dichlorobenzoyloxy radical (DCB⋅), much longer-lived linear RCOO⋅ has been suggested recently. We performed quantum chemical reaction pathway and spectral calculations. These calculations are in line with the experimental DCB⋅ decarboxylation dynamics and spectral properties and show that in contrast to DCB⋅, aliphatic RCOO⋅ radicals a) decarboxylate with a very low energetic barrier and on the timescale of a few ps and b) exhibit little red absorption. A time-resolved infrared spectroscopy experiment confirms very rapid, ≪300 ps RCOO⋅ decarboxylation in FAP. We argue that this property is required for the observed high quantum yield of hydrocarbons formation by FAP., (© 2024 Wiley‐VCH GmbH.)- Published
- 2024
- Full Text
- View/download PDF
21. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities.
- Author
-
Antonucci L, Thurman JM, and Vivarelli M
- Subjects
- Adult, Child, Humans, Complement Inactivating Agents therapeutic use, Complement Inactivating Agents pharmacology, Complement C3 metabolism, Complement Activation, Glomerulonephritis, Membranoproliferative drug therapy, Atypical Hemolytic Uremic Syndrome drug therapy, Kidney Diseases drug therapy
- Abstract
Historically, the complement system (classical, lectin, alternative, and terminal pathways) is known to play a crucial role in the etiopathogenesis of many kidney diseases. Direct or indirect activation in these settings is revealed by consumption of complement proteins at the serum level and kidney tissue deposition seen by immunofluorescence and electron microscopy. The advent of eculizumab has shown that complement inhibitors may improve the natural history of certain kidney diseases. Since then, the number of available therapeutic molecules and experimental studies on complement inhibition has increased exponentially. In our narrative review, we give a summary of the main complement inhibitors that have completed phase II and phase III studies or are currently used in adult and pediatric nephrology. The relevant full-text works, abstracts, and ongoing trials (clinicaltrials.gov site) are discussed. Data and key clinical features are reported for eculizumab, ravulizumab, crovalimab, avacopan, danicopan, iptacopan, pegcetacoplan, and narsoplimab. Many of these molecules have been shown to be effective in reducing proteinuria and stabilizing kidney function in different complement-mediated kidney diseases. Thanks to their efficacy and target specificity, these novel drugs may radically improve the outcome of complement-mediated kidney diseases, contributing to an improvement in our understanding of their underlying pathophysiology., (© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)
- Published
- 2024
- Full Text
- View/download PDF
22. The Past and Future of Inflammation as a Target to Cancer Prevention.
- Author
-
Antonucci L and Karin M
- Subjects
- Humans, Carcinogenesis, Inflammation complications, Neoplasms etiology, Neoplasms prevention & control
- Abstract
Inflammation is an essential defense mechanism in which innate immune cells are coordinately activated on encounter of harmful stimuli, including pathogens, tissue injury, and toxic compounds and metabolites to neutralize and eliminate the instigator and initiate healing and regeneration. Properly terminated inflammation is vital to health, but uncontrolled runaway inflammation that becomes chronic begets a variety of inflammatory and metabolic diseases and increases cancer risk. Making damaged tissues behave as "wounds that do not heal" and sustaining the production of growth factors whose physiologic function is tissue healing, chronic inflammation accelerates cancer emergence from premalignant lesions. In 1863, Rudolf Virchow, a leading German pathologist, suggested a possible association between inflammation and tumor formation, but it took another 140 years to fully elucidate and appreciate the tumorigenic role of inflammation. Key findings outlined molecular events in the inflammatory cascade that promote cancer onset and progression and enabled a better appreciation of when and where inflammation should be inhibited. These efforts triggered ongoing research work to discover and develop inflammation-reducing chemopreventive strategies for decreasing cancer risk and incidence., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
23. Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine.
- Author
-
Garzia I, Nocchi L, Avalle L, Troise F, Leoni G, Seclì L, Antonucci L, Cotugno G, Allocca S, Romano G, Conti L, Caiazza C, Mallardo M, Poli V, Scarselli E, and D'Alise AM
- Subjects
- Mice, Animals, Tumor Burden, CD8-Positive T-Lymphocytes, CD4-Positive T-Lymphocytes, Epitopes, Antigens, Neoplasm, Cancer Vaccines, Neoplasms
- Abstract
Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAgs required to induce tumor rejection. We selected clinically validated Great Ape-derived adenoviral vectors (GAd) as a nAg delivery system for differing numbers and combinations of nAgs. We assessed their immunogenicity and efficacy in murine models of low to high disease burden, comparing multi-epitope versus mono-epitope vaccines. We demonstrated that the breadth of immune response is critical for vaccine efficacy and having multiple immunogenic nAgs encoded in a single vaccine improves efficacy. The contribution of each single neoantigen was examined, leading to the identification of 2 nAgs able to induce CD8+ T cell-mediated tumor rejection. They were both active as individual nAgs in a setting of prophylactic vaccination, although to different extents. However, the efficacy of these single nAgs was lost in a setting of therapeutic vaccination in tumor-bearing mice. The presence of CD4+ T-cell help restored the efficacy for only the most expressed of the two nAgs, demonstrating a key role for CD4+ T cells in sustaining CD8+ T-cell responses and the necessity of an efficient recognition of the targeted epitopes on cancer cells by CD8+ T cells for an effective antitumor response. This study provides insight into understanding the determinants of nAgs relevant for effective treatment and highlights features that could contribute to more effective antitumor vaccines. See related Spotlight by Slingluff Jr, p. 382., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
24. Distinct multimodal biological and functional profiles of symptom-based subgroups in recent-onset psychosis.
- Author
-
Koutsouleris N, Buciuman MO, Vetter CS, Weyer CFC, Zhutovsky P, Perdomo ST, Khuntia A, Milaneschi Y, Popovic D, Ruef A, Dwyer D, Chisholm K, Kambeitz L, Antonucci L, Ruhrmann S, Kambeitz J, Riecher-Rössler A, Upthegrove R, Salokangas R, Hietala J, Pantelis C, Lencer R, Meisenzahl E, Wood S, Brambilla P, Borgwardt S, Bertolino A, and Falkai P
- Abstract
Symptom heterogeneity characterizes psychotic disorders and hinders the delineation of underlying biomarkers. Here, we identify symptom-based subtypes of recent-onset psychosis (ROP) patients from the multi-center PRONIA (Personalized Prognostic Tools for Early Psychosis Management) database and explore their multimodal biological and functional signatures. We clustered N = 328 ROP patients based on their maximum factor scores in an exploratory factor analysis on the Positive and Negative Syndrome Scale items. We assessed inter-subgroup differences and compared to N = 464 healthy control (HC) individuals regarding gray matter volume (GMV), neurocognition, polygenic risk scores, and longitudinal functioning trajectories. Finally, we evaluated factor stability at 9- and 18-month follow-ups. A 4-factor solution optimally explained symptom heterogeneity, showing moderate longitudinal stability. The ROP-MOTCOG ( Motor/Cognition ) subgroup was characterized by GMV reductions within salience, control and default mode networks, predominantly throughout cingulate regions, relative to HC individuals, had the most impaired neurocognition and the highest genetic liability for schizophrenia. ROP-SOCWD ( Social Withdrawal ) patients showed GMV reductions within medial fronto-temporal regions of the control, default mode, and salience networks, and had the lowest social functioning across time points. ROP-POS ( Positive ) evidenced GMV decreases in salience, limbic and frontal regions of the control and default mode networks. The ROP-AFF ( Affective ) subgroup showed GMV reductions in the salience, limbic, and posterior default-mode and control networks, thalamus and cerebellum. GMV reductions in fronto-temporal regions of the salience and control networks were shared across subgroups. Our results highlight the existence of behavioral subgroups with distinct neurobiological and functional profiles in early psychosis, emphasizing the need for refined symptom-based diagnosis and prognosis frameworks., Competing Interests: Conflict of Interest/Financial disclosure Dr Bertolino reports speaker fees from Otsuka, Lundbeck, Angelini and Rovi outside of the submitted work. Dr Hietala reports personal fees from Orion ltd, personal fees from Lundbeck, personal fees from Otsuka and other from Takeda during the conduct of the study. Dr Koutsouleris, Dr Ruhrmann, Dr Riecher-Rossler report grants from European Union over the duration of the study. Dr Meisenzahl and Dr Koutsouleris hold patent US20160192889A1 (‘Adaptive pattern recognition for psychosis risk modelling’). Dr Koutsouleris reports speaker fees from Otsuka, Roche and Angelini outside of the submitted work. Dr Pantelis reports grants from Australian NHMRC during the study, and personal fees from Lundbeck, Australia Pty Ltd outside the submitted work. Dr Upthegrove reports speaker fees from Sunovion, Otsuka and Vitaris outside the submitted work as well as unpaid officership with the British Association for Pharmacology - Honorary General Secretary 2021–2024. She serves as Deputy Editor for The British Journal of Psychiatry. Dr Falkai reports he has received research support/honoraria for lectures or advisory activities from Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Recordati and Richter outside the submitted work. Dr Pantelis was supported by an Australian National Health and Medical Research Council (NHMRC) L3 Investigator Grant (1196508) outside the submitted work. Dr Lana Kambeitz-Ilankovic reports receiving a NARSAD Young Investigator Award of the Brain & Behavior Research Foundation No° 28474 (PI: LK-I) outside the submitted work. Dr Milaneschi reports consulting fees from Noema Pharma outside the submitted work. Dr Upthegrove reports support from the UK NIHR Oxford Health Biomedical Research Centre. The views expressed are those of the author and not necessarily those of the NIHR or the Department of Health and Social Care. All other co-authors did not report any other financial disclosures or other conflicts of interests within or outside of the scope of the submitted work.
- Published
- 2024
- Full Text
- View/download PDF
25. Italian translation and transcultural validation of an assessment tool for community ambulation in stroke survivors: the modified Functional Walking Categories (mFWC).
- Author
-
Barbato C, Antonucci L, Pellicciari L, Castagnoli C, Hochleitner I, Paperini A, Pancani S, Verdesca S, Basagni B, Macchi C, and Cecchi F
- Subjects
- Humans, Reproducibility of Results, Psychometrics methods, Walking, Italy, Survivors, Surveys and Questionnaires, Quality of Life, Stroke diagnosis
- Abstract
Background: Community ambulation ability is one of the most important functional loss after stroke. The assessment of the level of community walking plays an important role in the multidimensional bio-psycho-social approach, to improve quality of life and social participation of stroke survivors. The modified Functional Walking Categories (mFWC) is a worldwide widely used tool to assess community ambulation in stroke survivors, but no Italian version is yet available., Objective: To cross-culturally adapt the mFWC into Italian and to assess its validity and reliability., Methods: According to the international guidelines, a multistep translation and cultural adaptation were conducted and revised by a committee of experts. Patients admitted to intensive inpatient rehabilitation with a sub-acute stroke were recruited. Inter- and intra-rater reliability and construct validity were studied., Results: Sixty patients with sub-acute stroke were prospectively enrolled in this study. Findings showed almost perfect intra- and inter-rater reliability (k = 1.000 [95% CI 1.000-1.000] and k = 0.984 [95% CI 0.955-1.000], respectively). The construct validity of the scale was satisfactory, as 100.0% a-priori hypotheses were met., Conclusions: The Italian mFWC offers a valid tool for measuring community ambulation in stroke patients. Our work provides a validated and a cross-cultural adapted Italian version of the mFWC to accurately measure community ambulation both in clinical and research settings in Italy.
- Published
- 2023
- Full Text
- View/download PDF
26. A simplified protocol of regional citrate anticoagulation with phosphate-containing solutions in infants and children treated with continuous kidney replacement therapy.
- Author
-
Cappoli A, Labbadia R, Antonucci L, Bottari G, Rossetti E, and Guzzo I
- Subjects
- Adult, Infant, Newborn, Humans, Child, Infant, Citric Acid adverse effects, Anticoagulants adverse effects, Phosphates, Critical Illness therapy, Magnesium, Citrates, Acute Kidney Injury etiology, Hemofiltration methods, Liver Failure
- Abstract
Background: Regional citrate anticoagulation (RCA) is the preferred modality of anticoagulation used in continuous kidney replacement therapy (CKRT) in adults and less extensively in children. Potential metabolic complications limit widespread use in infants, neonates, and in children with liver failure., Methods: We report our experience with a simplified protocol in 50 critically ill children, infants, and neonates, some of them with liver failure, with commercially available solutions containing phosphorous and higher concentration of potassium and magnesium., Results: RCA allowed attainment of a mean filter lifetime of 54.5 ± 18.2 h, 42.5% of circuits lasted more than 70 h, and scheduled change was the most frequent cause of CKRT interruption. Patient Ca
++ and circuit Ca++ were maintained in the target range with mean values of 1.15 ± 0.13 mmol/l and 0.38 ± 0.07 mmol/l, respectively. No session had to be stopped because of metabolic complications. The most frequent complications were hyponatremia, hypomagnesemia, and metabolic acidosis mostly related to primary disease and critical illness. No session had to be stopped because of citrate accumulation (CA). Transitory CA occurred in 6 patients and was managed without requiring RCA interruption. No patients with liver failure presented CA episodes., Conclusions: In our experience, RCA with commercially available solutions was easily applied and managed in critically ill children, even in patients with low weight or with liver failure. Solutions containing phosphate and higher concentrations of magnesium and potassium allowed reduction of metabolic derangement during CKRT. Prolonged filter life was ensured with no detrimental effects on patients and reduced staff workload. A higher resolution version of the Graphical abstract is available as Supplementary information., (© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)- Published
- 2023
- Full Text
- View/download PDF
27. A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide.
- Author
-
Antonucci L, Colucci M, Emma F, and Vivarelli M
- Subjects
- Male, Adult, Humans, Child, Adolescent, Prednisone therapeutic use, Hematuria, Proteinuria drug therapy, Budesonide therapeutic use, Glomerulonephritis, IGA diagnosis, Glomerulonephritis, IGA drug therapy, Glomerulonephritis, IGA etiology
- Abstract
Background: The best treatment for IgAN is still debated. The trials NEFIGAN and NEFIGARD have demonstrated that TRF-budesonide (Nefecon) efficiently and safely reduced proteinuria in adults, leading to FDA approval of Nefecon for adult IgAN. In pediatric IgAN, an etiological treatment does not yet exist, and the main therapies remain RAAS inhibitors and oral steroids. To our knowledge, this is one of the few pediatric reports of TRF-budesonide therapy., Case Report-Diagnosis/treatment: A 13-year-old boy underwent a kidney biopsy for recurrent macrohematuria and proteinuria, resulting in an IgAN diagnosis (MEST-C score M1-E1-S0-T0-C1). At admission, serum creatinine and UPCR were slightly increased. Three methylprednisolone pulses were performed, followed by prednisone and RAAS inhibitors therapy. However, after 10 months, macrohematuria became constant, and UPCR increased. A new kidney biopsy was performed, showing an increase in sclerotic lesions. Prednisone was discontinued, and a trial with IBD TRF-budesonide 9 mg/day started. One month later, macrohematuria episodes disappeared and UPCR decreased, with a stable kidney function. After 5 months, due to a reduction in morning cortisol levels and difficulty in drug provisioning, we started to wean TRF-budesonide by 3 mg every 3 months, with complete withdrawal after 1 year. During this period, episodes of macrohematuria dramatically decreased, and UPCR and kidney function were maintained stable., Conclusion: Our case demonstrates that TRF-budesonide could be considered an effective second-line treatment in pediatric IgAN, particularly when a long course of steroids is necessary to control active inflammation. However, pediatric clinical trials to identify the correct dosage and tolerability of TRF-budesonide are urgently needed., (© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)
- Published
- 2023
- Full Text
- View/download PDF
28. α-Tocopherol Protects Lipopolysaccharide-Activated BV2 Microglia.
- Author
-
La Torre ME, Cianciulli A, Monda V, Monda M, Filannino FM, Antonucci L, Valenzano A, Cibelli G, Porro C, Messina G, Panaro MA, Messina A, and Polito R
- Subjects
- Humans, Lipopolysaccharides pharmacology, Microglia, alpha-Tocopherol pharmacology, alpha-Tocopherol metabolism, Phosphatidylinositol 3-Kinases metabolism, Macrophages metabolism, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents metabolism, Vitamin E pharmacology, Nitric Oxide metabolism, NF-kappa B metabolism, Neuroprotective Agents pharmacology, Neuroprotective Agents metabolism, Neurodegenerative Diseases drug therapy, Neurodegenerative Diseases prevention & control, Neurodegenerative Diseases metabolism
- Abstract
Microglia, the resident macrophage-like population in the central nervous system, play a crucial role in the pathogenesis of many neurodegenerative disorders by triggering an inflammatory response that leads to neuronal death. Neuroprotective compounds to treat or prevent neurodegenerative diseases are a new field of study in modern medicine. Microglia are activated in response to inflammatory stimuli. The pathogenesis of various neurodegenerative diseases is closely related to the constant activation of microglia due to their fundamental role as a mediator of inflammation in the brain environment. α-Tocopherol, also known as vitamin E, is reported to possess potent neuroprotective effects. The goal of this study was to investigate the biological effects of vitamin E on BV2 microglial cells, as a possible neuroprotective and anti-inflammatory agent, following stimulation with lipopolysaccharide (LPS). The results showed that the pre-incubation of microglia with α-tocopherol can guarantee neuroprotective effects during microglial activation induced by LPS. α-Tocopherol preserved the branched morphology typical of microglia in a physiological state. It also reduced the migratory capacity; the production of pro-inflammatory and anti-inflammatory cytokines such as TNF-α and IL-10; and the activation of receptors such as TRL4 and CD40, which modulate the PI3K-Akt signaling pathway. The results of this study require further insights and research, but they present new scenarios for the application of vitamin E as an antioxidant for the purpose of greater neuroprotection in vivo for the prevention of possible neurodegenerative diseases.
- Published
- 2023
- Full Text
- View/download PDF
29. Extracellular Vesicles Cargo in Modulating Microglia Functional Responses.
- Author
-
La Torre ME, Panaro MA, Ruggiero M, Polito R, Cianciulli A, Filannino FM, Lofrumento DD, Antonucci L, Benameur T, Monda V, Monda M, Porro C, and Messina G
- Abstract
Extracellular vesicles (EVs) represent a heterogeneous group of membranous structures derived from cells that are released by all cell types, including brain cells. EVs are now thought to be an additional mechanism of intercellular communication. Both under normal circumstances and following the addition of proinflammatory stimuli, microglia release EVs, but the contents of these two types of EVs are different. Microglia are considered the brain-resident immune cells that are involved in immune surveillance and inflammatory responses in the central nervous system. In this research, we have analyzed the effects of EVs isolated from microglia in response to LPS (Lipopolysaccharide) on microglia activation. The EVs produced as result of LPS stimulation, knows as EVs-LPS, were then used as stimuli on microglia BV2 resting cells in order to investigate their ability to induce microglia to polarize towards an inflammatory state. After EVs-LPS stimulation, we analyzed the change to BV2 cells' morphology, proliferation, and migration, and investigated the expression and the release of pro-inflammatory cytokines. The encouraging findings of this study showed that EVs-LPS can activate microglia in a manner similar to that of LPS alone and that EVs derived from control cells cannot polarize microglia towards a pro-inflammatory state. This study has confirmed the critical role of EVs in communication and shown how EVs produced in an inflammatory environment can exacerbate the inflammatory process by activating microglia, which may have an impact on all brain cells., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2022
- Full Text
- View/download PDF
30. Italian translation and cross-cultural validation of an assessment tool for participation in stroke survivors: the Frenchay Activities Index.
- Author
-
Antonucci L, Barbato C, Pellicciari L, Paperini A, Hochleitner I, Castagnoli C, Verdesca S, Lucidi G, Marignani S, Pancani S, Basagni B, Macchi C, and Cecchi F
- Subjects
- Cross-Cultural Comparison, Humans, Psychometrics methods, Reproducibility of Results, Surveys and Questionnaires, Survivors, Translations, Stroke, Stroke Rehabilitation methods
- Abstract
Purpose: Participation needs to be assessed objectively, to state accurate rehabilitation objectives. The Frenchay Activities Index (FAI) is a widely used tool to measure participation in stroke patients. To date, no cross-culturally validated Italian version of FAI is available. This study provides a translation and cross-cultural adaptation of FAI into Italian, assessing its validity and reliability in sub-acute stroke patients., Methods: According to international guidelines, a multistep translation and cultural adaptation protocol of forward and backward translations was conducted by qualified linguists and independent native English translators and revised by a healthcare committee. Patients admitted to intensive inpatient rehabilitation after stroke were recruited. Structural validity, reliability (internal consistency, inter- and intra-rater reliability and measurement error), and construct validity were studied., Results: One hundred and seventy-three patients were included in this study. No significant observations in terms of comprehensibility and conceptual equivalence of the FAI Italian version emerged. The exploratory factorial analysis revealed the presence of two subscales (i.e., domestic chores and work/leisure). The internal consistency resulted good for the first and second subscale (α = 0.821 and 0.716, respectively). Intra- and inter-reliability showed an ICC > 0.90 for both subscales. SEM = 5.75% and 2.33% and MDC = 15.85% and 6.48% were found for the first and second subscale, respectively. Construct validity of first subscale was satisfactory, as 100.0% a priori hypotheses were met, while for the second subscale it was moderate, as 66.6% a priori hypotheses were respected., Conclusion: FAI-I provides a tool for professionals to measure participation in Italian stroke patients in health and social care settings., (© 2022. Fondazione Società Italiana di Neurologia.)
- Published
- 2022
- Full Text
- View/download PDF
31. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
- Author
-
Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, and Del Bufalo F
- Subjects
- Child, Humans, Immunotherapy, Adoptive methods, Tumor Microenvironment, Glioblastoma, Liver Neoplasms, Pediatrics, Receptors, Chimeric Antigen genetics
- Abstract
High-Grade Gliomas (HGG) are among the deadliest malignant tumors of central nervous system (CNS) in pediatrics. Despite aggressive multimodal treatment - including surgical resection, radiotherapy and chemotherapy - long-term prognosis of patients remains dismal with a 5-year survival rate less than 20%. Increased understanding of genetic and epigenetic features of pediatric HGGs (pHGGs) revealed important differences with adult gliomas, which need to be considered in order to identify innovative and more effective therapeutic approaches. Immunotherapy is based on different techniques aimed to redirect the patient own immune system to fight specifically cancer cells. In particular, T-lymphocytes can be genetically modified to express chimeric proteins, known as chimeric antigen receptors (CARs), targeting selected tumor-associated antigens (TAA). Disialoganglioside GD2 (GD-2) and B7-H3 are highly expressed on pHGGs and have been evaluated as possible targets in pediatric clinical trials, in addition to the antigens common to adult glioblastoma - such as interleukin-13 receptor alpha 2 (IL-13α2), human epidermal growth factor receptor 2 (HER-2) and erythropoietin-producing human hepatocellular carcinoma A2 receptor (EphA2). CAR-T therapy has shown promise in preclinical model of pHGGs but failed to achieve the same success obtained for hematological malignancies. Several limitations, including the immunosuppressive tumor microenvironment (TME), the heterogeneity in target antigen expression and the difficulty of accessing the tumor site, impair the efficacy of T-cells. pHGGs display an immunologically cold TME with poor T-cell infiltration and scarce immune surveillance. The secretion of immunosuppressive cytokines (TGF-β, IL-10) and the presence of immune-suppressive cells - like tumor-associated macrophages/microglia (TAMs) and myeloid-derived suppressor cells (MDSCs) - limit the effectiveness of immune system to eradicate tumor cells. Innovative immunotherapeutic strategies are necessary to overcome these hurdles and improve ability of T-cells to eradicate tumor. In this review we describe the distinguishing features of HGGs of the pediatric population and of their TME, with a focus on the most promising CAR-T therapies overcoming these hurdles., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Antonucci, Canciani, Mastronuzzi, Carai, Del Baldo and Del Bufalo.)
- Published
- 2022
- Full Text
- View/download PDF
32. Periprosthetic femoral fractures in Total Hip Arthroplasty (THA): a comparison between osteosynthesis and revision in a retrospective cohort study.
- Author
-
Scalici G, Boncinelli D, Zanna L, Buzzi R, Antonucci L, Di Maida F, and De Biase P
- Subjects
- Femur surgery, Fracture Fixation, Internal adverse effects, Fracture Fixation, Internal methods, Humans, Reoperation adverse effects, Retrospective Studies, Arthroplasty, Replacement, Hip adverse effects, Femoral Fractures etiology, Femoral Fractures surgery, Periprosthetic Fractures epidemiology, Periprosthetic Fractures etiology, Periprosthetic Fractures surgery
- Abstract
Background: Periprosthetic femoral fractures are challenging complications of hip arthroplasty. They are supposed to be a rare complication, but their incidence is rapidly increasing. Surgical treatment aims to achieve early mobilization and avoid the complications of prolonged bed rest. Aim of this study is to evaluate the clinical outcomes of surgical treatment comparing two surgical approaches: revision arthroplasty (RA) versus open reduction and internal fixation (ORIF)., Methods: Authors retrospectively reviewed a series of 117 patients with total hip arthroplasty treated for periprosthetic femur fractures in the period between January 2013 and March 2018 at a single tertiary referral center. Of these, 70 patients satisfied strict inclusion criteria. Patients were classified according to the Unified Classification System (UCS) and distributed in two groups according to surgical treatment. Clinical outcomes were assessed using the Oxford Hip recorded preoperatively and post operatively, Barthel Score, CIRS score (Cumulative illness rating scale), type of fracture and post-operative complications with a minimum follow up of 1 year., Results: Nominal univariate statistical analysis revealed significant differences between the post and pre-operative Oxford Hip Score (Δ Oxford) and the surgical treatment (p = 0.008) and CIRS score (p = 0.048). Moreover, we observed a significant relationship between type of treatment and type of fracture (p = 0.0001). Multivariate analyses revealed that CIRS score was independently associated with Oxford Score improvement after surgery (p = 0.024)., Conclusions: Data from this case series confirmed that surgical treatment was correlated to type of fracture, according to UCS classification. Patients treated by RA had a better functional outcome than patients treated with ORIF, but these results are strongly influenced from the patients' age, Barthel index and CIRS score. Also, authors found a correlation between functional outcome and comorbidities evaluated by CIRS score. Based on these data we suggest a multimodal approach to these patients, like those used for proximal femoral fractures., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
33. Impact of the SARS-CoV-2 pandemic and associated restrictions on Pediatric Emergency Department utilization in Sardinia: a retrospective bicentric observational study.
- Author
-
Antonucci R, Clemente MG, Antonucci L, Canetto A, Mastromattei S, Chiapello N, Vacca N, Saderi L, Sotgiu G, and Locci C
- Subjects
- Child, Communicable Disease Control, Emergency Service, Hospital, Humans, Italy epidemiology, Retrospective Studies, SARS-CoV-2, COVID-19 epidemiology, Pandemics
- Abstract
Background: The COVID-19 pandemic and associated public health measures have had a profound impact on health systems worldwide. The aim of this study was to assess quantitative and qualitative changes in Pediatric Emergency Department (PED) visits in Sardinia, Italy, during the early period of the COVID-19 pandemic., Methods: We retrospectively investigated the number and characteristics of visits to two major Sardinian PEDs, in the periods January-June 2020 and January-June 2019., Results: From January to June 2020, 8399 PED visits with 1160 hospital admissions (13.8% of PED visits) were registered, compared with 15,692 PED visits (Δ = -46.5%) and 1819 hospital admissions (11.6% of PED visits) occurring from January to June 2019. Comparing January-June 2020 with January-June 2019, we found differences in the percentage of visits for age groups, and significant changes in the proportion of triage codes, with a decrease in green codes (72.1% vs 74.2%, respectively) and an increase in white codes (19.0% vs 16.5%, respectively). Moreover, in the period January-June 2020, the frequency of skin disorders and acute respiratory disease significantly decreased, while the frequency of trauma, acute surgical disease, intoxication, and neuropsychiatric disease significantly increased., Conclusions: After the beginning of the Italian lockdown, we observed a marked drop in the number of PED visits, an increase in hospital admission rate, and radical changes in the reason for visit., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. Reversible glomerular damage in disseminated intravascular coagulation.
- Author
-
Labbadia R, Diomedi Camassei F, Antonucci L, Guzzo I, Onetti Muda A, Spada M, and Dello Strologo L
- Subjects
- Adolescent, Disseminated Intravascular Coagulation etiology, Female, Graft Survival, Humans, Kidney Glomerulus transplantation, Male, Brain Injuries, Traumatic physiopathology, Disseminated Intravascular Coagulation pathology, Donor Selection methods, Kidney Glomerulus pathology, Kidney Transplantation
- Abstract
Background: Brain death secondary to traumatic brain injury is one of the main sources of organs for transplantation but it can be associated with disseminated intravascular coagulation, which has been considered a relative contraindication for kidney donation., Methods: We describe two successful pediatric cases of kidney transplantation from a single donor with disseminated intravascular coagulation., Results: A 17-year-old male donor died from head injury and both kidneys were offered to our center. Within 24 h, donor's Hb and platelets dropped to 8.3 g/dl and 32 000/mcl, respectively, serum creatinine reached 2.01 mg/dl, and urinalysis showed proteinuria (300 mg/dl). Pre-implant biopsy showed massive occlusion of glomerular capillaries by fibrin thrombi containing fragmented red blood cells and inflammatory cells, and acute tubular damage. Arterioles and small arteries were spared. A diagnosis of DIC was made. The kidneys were transplanted in a 16-year-old girl and a 13-year-old boy. Slow recovery of graft function was observed in both recipients. On post-operative day 3, platelets dropped to a minimum value of 66 000 and 86 000/mcl, respectively. Diuresis was always present. On day 4, platelets started to rise. Six months later, both recipients attained normal renal function. A six-month protocol biopsy showed no microthrombi or other signs of disseminated intravascular coagulation., Conclusions: Despite the limited data available in literature, the outcome of these two cases is positive. Thus, pre-implant kidney biopsy, even if it reveals massive thrombotic occlusion of glomerular capillaries compatible with diagnosis of disseminated intravascular coagulation, should not be considered an absolute contraindication to transplantation., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
35. Insecure attachment as a transdiagnostic risk factor for major psychiatric conditions: A meta-analysis in bipolar disorder, depression and schizophrenia spectrum disorder.
- Author
-
Herstell S, Betz LT, Penzel N, Chechelnizki R, Filihagh L, Antonucci L, and Kambeitz J
- Subjects
- Depression diagnosis, Humans, Risk Factors, Bipolar Disorder epidemiology, Depressive Disorder, Major, Schizophrenia epidemiology
- Abstract
Insecure attachment has been suggested as a major risk factor for mental health problems as well as a key element for the development and trajectory of psychiatric disorders. The aim of this meta-analysis was to assess whether insecure attachment constitutes a global transdiagnostic risk factor in bipolar disorder, depression, and schizophrenia spectrum disorders. We conducted a PRISMA-based systematic quantitative review to explore the prevalence of insecure attachment among patients of three representative psychiatric disorders - major depression, schizophrenia spectrum disorders and bipolar disorder - in comparison with healthy controls (HC) from a transdiagnostic point of view. Effect sizes on differences of anxious, avoidant and insecure prevalence were calculated based on 40 samples including a total of n = 2927 individuals. Overall, results indicated a large effect on prevalence of insecure attachment across all disorders compared to HC (k = 30, g = 0.88, I
2 = 71.0%, p < 0.001). In a transdiagnostic comparison, the only difference was found in avoidant attachment, which was significantly lower (p = 0.04) compared to HC in the schizophrenia spectrum disorder subgroup (k = 10, g = 0.31, I2 = 76.60%, p < 0.0001) than the depression subgroup subgroup (k = 12, g = 0.83, I2 = 46.65%, p < 0.0001). The lack of further transdiagnostic differences between three distinct psychiatric disorders corroborates insecure attachment as a general vulnerability factor to psychopathology. Our findings warrant further investigations, which should explore the pathways from attachment insecurity towards psychopathology. Insecure attachment likely has implications on assessment, prediction and treatment of psychiatric patients., (Copyright © 2021. Published by Elsevier Ltd.)- Published
- 2021
- Full Text
- View/download PDF
36. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
- Author
-
Tumino N, Weber G, Besi F, Del Bufalo F, Bertaina V, Paci P, Quatrini L, Antonucci L, Sinibaldi M, Quintarelli C, Maggi E, De Angelis B, Locatelli F, Moretta L, Vacca P, and Caruana I
- Subjects
- Humans, Myeloid-Derived Suppressor Cells pathology, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local pathology, Neuroblastoma immunology, Neuroblastoma pathology, Treatment Outcome, Immunotherapy, Adoptive methods, Myeloid-Derived Suppressor Cells immunology, Neuroblastoma therapy
- Abstract
The outcome of patients affected by high-risk or metastatic neuroblastoma (NB) remains grim, with ≥ 50% of the children experiencing relapse or progression of the disease despite multimodal, intensive treatment. In order to identify new strategies to improve the overall survival and the quality of life of these children, we recently developed and optimized a third-generation GD2-specific chimeric antigen receptor (CAR) construct, which is currently under evaluation in our Institution in a phase I/II clinical trial (NCT03373097) enrolling patients with relapsed/refractory NB. We observed that our CAR T-cells are able to induce marked tumor reduction and even achieve complete remission with a higher efficiency than that of other CAR T-cells reported in previous studies. However, often responses are not sustained and relapses occur. Here, we demonstrate for the first time a mechanism of resistance to GD2.CAR T-cell treatment, showing how polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) increase in the peripheral blood (PB) of NB patients after GD2.CAR T-cell treatment in case of relapse and loss of response. In vitro, isolated PMN-MDSC demonstrate to inhibit the anti-tumor cytotoxicity of different generations of GD2.CAR T-cells. Gene-expression profiling of GD2.CAR T-cells "conditioned" with PMN-MDSC shows downregulation of genes involved in cell activation, signal transduction, inflammation and cytokine/chemokine secretion. Analysis of NB gene-expression dataset confirms a correlation between expression of these genes and patient outcome. Moreover, in patients treated with GD2.CAR T-cells, the frequency of circulating PMN-MDSC inversely correlates with the levels of GD2.CAR T-cells, resulting more elevated in patients who did not respond or lost response to the treatment. The presence and the frequency of PMN-MDSC in PB of high-risk and metastatic NB represents a useful prognostic marker to predict the response to GD2.CAR T-cells and other adoptive immunotherapy. This study underlines the importance of further optimization of both CAR T-cells and clinical trial in order to target elements of the tumor microenvironment., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
37. Infant botulism: an underestimated threat.
- Author
-
Antonucci L, Locci C, Schettini L, Clemente MG, and Antonucci R
- Subjects
- Child, Humans, Infant, Botulism diagnosis, Botulism epidemiology, Botulism therapy, Clostridium botulinum
- Abstract
Infant botulism (IB) is defined as a potentially life-threatening neuroparalytic disorder affecting children younger than 12 months. It is caused by ingestion of food or dust contaminated by Clostridium botulinum spores, which germinate in the infant's large bowel and produce botulinum neurotoxin. Although the real impact of IB is likely underestimated worldwide, the USA has the highest number of cases. The limited reporting of IB in many countries is probably due to diagnostic difficulties and nonspecific presentation. The onset is usually heralded by constipation, followed by bulbar palsy, and then by a descending bilateral symmetric paralysis; ultimately, palsy can involve respiratory and diaphragmatic muscles, leading to respiratory failure. The treatment is based on supportive care and specific therapy with Human Botulism Immune Globulin Intravenous (BIG-IV), and should be started as early as possible. The search for new human-like antibody preparations that are both highly effective and well tolerated has led to the creation of a mixture of oligoclonal antibodies that are highly protective and can be produced in large quantities without the use of animals. Ongoing research for future treatment of IB involves the search for new molecular targets to produce a new generation of laboratory-produced antitoxins, and the development of new vaccines with safety and efficacy profiles that can be scaled up for clinical use. This narrative literature review aims to provide a readable synthesis of the best current literature on microbiological, epidemiological and clinical features of IB, and a practical guide for its treatment.
- Published
- 2021
- Full Text
- View/download PDF
38. Classification of first-episode psychosis using cortical thickness: A large multicenter MRI study.
- Author
-
Pigoni A, Dwyer D, Squarcina L, Borgwardt S, Crespo-Facorro B, Dazzan P, Smesny S, Spaniel F, Spalletta G, Sanfelici R, Antonucci LA, Reuf A, Oeztuerk OF, Schmidt A, Ciufolini S, Schönborn-Harrisberger F, Langbein K, Gussew A, Reichenbach JR, Zaytseva Y, Piras F, Delvecchio G, Bellani M, Ruggeri M, Lasalvia A, Tordesillas-Gutiérrez D, Ortiz V, Murray RM, Reis-Marques T, Di Forti M, Koutsouleris N, and Brambilla P
- Subjects
- Adult, Brain, Female, Humans, Magnetic Resonance Imaging methods, Neuroimaging, Support Vector Machine, Psychotic Disorders diagnostic imaging
- Abstract
Machine learning classifications of first-episode psychosis (FEP) using neuroimaging have predominantly analyzed brain volumes. Some studies examined cortical thickness, but most of them have used parcellation approaches with data from single sites, which limits claims of generalizability. To address these limitations, we conducted a large-scale, multi-site analysis of cortical thickness comparing parcellations and vertex-wise approaches. By leveraging the multi-site nature of the study, we further investigated how different demographical and site-dependent variables affected predictions. Finally, we assessed relationships between predictions and clinical variables. 428 subjects (147 females, mean age 27.14) with FEP and 448 (230 females, mean age 27.06) healthy controls were enrolled in 8 centers by the ClassiFEP group. All subjects underwent a structural MRI and were clinically assessed. Cortical thickness parcellation (68 areas) and full cortical maps (20,484 vertices) were extracted. Linear Support Vector Machine was used for classification within a repeated nested cross-validation framework. Vertex-wise thickness maps outperformed parcellation-based methods with a balanced accuracy of 66.2% and an Area Under the Curve of 72%. By stratifying our sample for MRI scanner, we increased generalizability across sites. Temporal brain areas resulted as the most influential in the classification. The predictive decision scores significantly correlated with age at onset, duration of treatment, and positive symptoms. In conclusion, although far from the threshold of clinical relevance, temporal cortical thickness proved to classify between FEP subjects and healthy individuals. The assessment of site-dependent variables permitted an increase in the across-site generalizability, thus attempting to address an important machine learning limitation., Competing Interests: Conflicts of Interest All authors declare that they have no conflicts of interest., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
39. TFG binds LC3C to regulate ULK1 localization and autophagosome formation.
- Author
-
Carinci M, Testa B, Bordi M, Milletti G, Bonora M, Antonucci L, Ferraina C, Carro M, Kumar M, Ceglie D, Eck F, Nardacci R, le Guerroué F, Petrini S, Soriano ME, Caruana I, Doria V, Manifava M, Peron C, Lambrughi M, Tiranti V, Behrends C, Papaleo E, Pinton P, Giorgi C, Ktistakis NT, Locatelli F, Nazio F, and Cecconi F
- Subjects
- Autophagy-Related Protein-1 Homolog genetics, Blotting, Western, Fluorescent Antibody Technique, HEK293 Cells, HeLa Cells, Humans, Immunoprecipitation, Intracellular Signaling Peptides and Proteins genetics, Microscopy, Electron, Transmission, Microtubule-Associated Proteins genetics, Proteins genetics, RNA Interference, Autophagosomes metabolism, Autophagy-Related Protein-1 Homolog metabolism, Intracellular Signaling Peptides and Proteins metabolism, Microtubule-Associated Proteins metabolism, Proteins metabolism
- Abstract
The early secretory pathway and autophagy are two essential and evolutionarily conserved endomembrane processes that are finely interlinked. Although growing evidence suggests that intracellular trafficking is important for autophagosome biogenesis, the molecular regulatory network involved is still not fully defined. In this study, we demonstrate a crucial effect of the COPII vesicle-related protein TFG (Trk-fused gene) on ULK1 puncta number and localization during autophagy induction. This, in turn, affects formation of the isolation membrane, as well as the correct dynamics of association between LC3B and early ATG proteins, leading to the proper formation of both omegasomes and autophagosomes. Consistently, fibroblasts derived from a hereditary spastic paraparesis (HSP) patient carrying mutated TFG (R106C) show defects in both autophagy and ULK1 puncta accumulation. In addition, we demonstrate that TFG activity in autophagy depends on its interaction with the ATG8 protein LC3C through a canonical LIR motif, thereby favouring LC3C-ULK1 binding. Altogether, our results uncover a link between TFG and autophagy and identify TFG as a molecular scaffold linking the early secretion pathway to autophagy., (© 2021 The Authors. Published under the terms of the CC BY NC ND 4.0 license.)
- Published
- 2021
- Full Text
- View/download PDF
40. Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis.
- Author
-
Su H, Yang F, Fu R, Li X, French R, Mose E, Pu X, Trinh B, Kumar A, Liu J, Antonucci L, Todoric J, Liu Y, Hu Y, Diaz-Meco MT, Moscat J, Metallo CM, Lowy AM, Sun B, and Karin M
- Subjects
- Animals, Autophagy genetics, Carcinoma, Pancreatic Ductal immunology, Mice, NF-E2-Related Factor 2 pharmacology, Oxidative Stress drug effects, Oxidative Stress physiology, Pancreatic Neoplasms immunology, Pinocytosis immunology, Pinocytosis physiology, Sequestosome-1 Protein metabolism, Signal Transduction immunology, Signal Transduction physiology, Pancreatic Neoplasms, Autophagy physiology, Carcinoma, Pancreatic Ductal metabolism, NF-E2-Related Factor 2 metabolism, Pancreatic Neoplasms metabolism
- Abstract
Many cancers, including pancreatic ductal adenocarcinoma (PDAC), depend on autophagy-mediated scavenging and recycling of intracellular macromolecules, suggesting that autophagy blockade should cause tumor starvation and regression. However, until now autophagy-inhibiting monotherapies have not demonstrated potent anti-cancer activity. We now show that autophagy blockade prompts established PDAC to upregulate and utilize an alternative nutrient procurement pathway: macropinocytosis (MP) that allows tumor cells to extract nutrients from extracellular sources and use them for energy generation. The autophagy to MP switch, which may be evolutionarily conserved and not cancer cell restricted, depends on activation of transcription factor NRF2 by the autophagy adaptor p62/SQSTM1. NRF2 activation by oncogenic mutations, hypoxia, and oxidative stress also results in MP upregulation. Inhibition of MP in autophagy-compromised PDAC elicits dramatic metabolic decline and regression of transplanted and autochthonous tumors, suggesting the therapeutic promise of combining autophagy and MP inhibitors in the clinic., Competing Interests: Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and of the scientific advisory board of the Joint Center for Life Sciences, and receives research support from Merck, Janssen, and Gossamer. H.S. and M.K. are authors/inventors of patent titled (Combination therapy for cancer), (PCT/US2021/013203), and (2021) (patent is pending approval)., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
41. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
- Author
-
Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Ferrari F, Salviato E, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Brenner MK, Gottschalk S, Hoyos V, Locatelli F, Caruana I, and Del Bufalo F
- Subjects
- Adenoviridae metabolism, Adenoviridae pathogenicity, Animals, Antibodies, Bispecific metabolism, Apoptosis, Brain Neoplasms genetics, Brain Neoplasms metabolism, Brain Neoplasms virology, Cell Line, Tumor, Coculture Techniques, Cytotoxicity, Immunologic, Female, Gene Expression Regulation, Neoplastic, Genetic Vectors, Glioma genetics, Glioma metabolism, Glioma virology, Humans, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Mice, Inbred NOD, Mice, SCID, Neoplasm Grading, Oncolytic Viruses metabolism, Oncolytic Viruses pathogenicity, Receptor, EphA2 metabolism, T-Lymphocytes immunology, T-Lymphocytes metabolism, Xenograft Model Antitumor Assays, Mice, Adenoviridae genetics, Antibodies, Bispecific genetics, Brain Neoplasms therapy, Genetic Therapy, Glioma therapy, Oncolytic Virotherapy, Oncolytic Viruses genetics, Receptor, EphA2 genetics
- Abstract
Background: Pediatric high-grade gliomas (pHGGs) are among the most common and incurable malignant neoplasms of childhood. Despite aggressive, multimodal treatment, the outcome of children with high-grade gliomas has not significantly improved over the past decades, prompting the development of innovative approaches., Methods: To develop an effective treatment, we aimed at improving the suboptimal antitumor efficacy of oncolytic adenoviruses (OAs) by testing the combination with a gene-therapy approach using a bispecific T-cell engager (BiTE) directed towards the erythropoietin-producing human hepatocellular carcinoma A2 receptor (EphA2), conveyed by a replication-incompetent adenoviral vector (EphA2 adenovirus (EAd)). The combinatorial approach was tested in vitro, in vivo and thoroughly characterized at a molecular level., Results: After confirming the relevance of EphA2 as target in pHGGs, documenting a significant correlation with worse clinical outcome of the patients, we showed that the proposed strategy provides significant EphA2-BiTE amplification and enhanced tumor cell apoptosis, on coculture with T cells. Moreover, T-cell activation through an agonistic anti-CD28 antibody further increased the activation/proliferation profiles and functional response against infected tumor cells, inducing eradication of highly resistant, primary pHGG cells. The gene-expression analysis of tumor cells and T cells, after coculture, revealed the importance of both EphA2-BiTE and costimulation in the proposed system. These in vitro observations translated into significant tumor control in vivo, in both subcutaneous and a more challenging orthotopic model., Conclusions: The combination of OA and EphA2-BiTE gene therapy strongly enhances the antitumor activity of OA, inducing the eradication of highly resistant tumor cells, thus supporting the clinical translation of the approach., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
42. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
- Author
-
Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, and Shalapour S
- Subjects
- Animals, Antineoplastic Agents pharmacology, Apoptosis, B7-H1 Antigen genetics, B7-H1 Antigen metabolism, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, CD8-Positive T-Lymphocytes, Cell Proliferation, Drug Therapy, Combination, Humans, Immunotherapy methods, Mice, NF-kappa B genetics, Neoplasms immunology, Neoplasms metabolism, Neoplasms pathology, Oxaliplatin pharmacology, Prognosis, Survival Rate, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, p300-CBP Transcription Factors genetics, Antigen Presentation immunology, Gene Expression Regulation, Neoplastic drug effects, Histocompatibility Antigens Class I immunology, Immune Checkpoint Inhibitors pharmacology, NF-kappa B metabolism, Neoplasms drug therapy, p300-CBP Transcription Factors metabolism
- Abstract
Many cancers evade immune rejection by suppressing major histocompatibility class I (MHC-I) antigen processing and presentation (AgPP). Such cancers do not respond to immune checkpoint inhibitor therapies (ICIT) such as PD-1/PD-L1 [PD-(L)1] blockade. Certain chemotherapeutic drugs augment tumor control by PD-(L)1 inhibitors through potentiation of T-cell priming but whether and how chemotherapy enhances MHC-I-dependent cancer cell recognition by cytotoxic T cells (CTLs) is not entirely clear. We now show that the lysine acetyl transferases p300/CREB binding protein (CBP) control MHC-I AgPPM expression and neoantigen amounts in human cancers. Moreover, we found that two distinct DNA damaging drugs, the platinoid oxaliplatin and the topoisomerase inhibitor mitoxantrone, strongly up-regulate MHC-I AgPP in a manner dependent on activation of nuclear factor kappa B (NF-κB), p300/CBP, and other transcription factors, but independently of autocrine IFNγ signaling. Accordingly, NF-κB and p300 ablations prevent chemotherapy-induced MHC-I AgPP and abrogate rejection of low MHC-I-expressing tumors by reinvigorated CD8
+ CTLs. Drugs like oxaliplatin and mitoxantrone may be used to overcome resistance to PD-(L)1 inhibitors in tumors that had "epigenetically down-regulated," but had not permanently lost MHC-I AgPP activity., Competing Interests: Competing interest statement: I.M., J.R.L., R.B., Q.T.P. and G.H. are employees of Genentech.- Published
- 2021
- Full Text
- View/download PDF
43. Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough?
- Author
-
Cuzzolin L, Oggiano AM, Clemente MG, Locci C, Antonucci L, and Antonucci R
- Subjects
- Child, Cholelithiasis therapy, Humans, Anti-Bacterial Agents adverse effects, Ceftriaxone adverse effects, Cholelithiasis chemically induced
- Abstract
Ceftriaxone is an antibiotic agent frequently used in paediatric hospital practice for the treatment of severe bacterial infections. The use of this agent can result in cholelithiasis and/or biliary sludge, more commonly in children than in adults. This systematic review was aimed at analysing available literature concerning ceftriaxone-associated biliary pseudolithiasis in paediatric patients, with a special emphasis on the clinical aspects. A literature analysis was performed using Medline and Embase electronic databases (articles published in English up to December 2019), with the search terms and combinations as follows:'ceftriaxone', 'cholelithiasis', 'biliary sludge' 'gallstones' 'neonates' 'children' 'clinical aspects' 'management'. Several case reports, case series and prospective/retrospective studies have documented a relationship between ceftriaxone treatment and biliary pseudolithiasis in the paediatric population, even though literature data regarding neonates and infants are scarce. Ceftriaxone-associated biliary pseudolithiasis is dose-dependent and usually asymptomatic but, sometimes, it may present with abdominal pain, nausea and emesis. Abdominal ultrasonography should be performed when this complication is suspected. Generally, ceftriaxone-associated cholelithiasis resolves over a variable period of time (days to months) after cessation of therapy. Therefore, a conservative approach to this condition is advocated, but a prolonged follow-up may be necessary. A personalized assessment of factors predisposing to ceftriaxone-associated biliary pseudolithiasis before prescribing the drug can allow to minimize the risk of developing it, with significant advantages in terms of human and economic costs., (© 2020 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2021
- Full Text
- View/download PDF
44. Disability and sustainability: reusable versus single-use catheters for persons with neurogenic bladder due to spinal cord injury.
- Author
-
Del Popolo G and Antonucci L
- Subjects
- Catheters adverse effects, Humans, Spinal Cord Injuries rehabilitation, Urinary Bladder physiopathology, Urinary Catheterization methods, Disabled Persons rehabilitation, Spinal Cord Injuries complications, Spinal Cord Injuries surgery, Urinary Bladder, Neurogenic surgery
- Published
- 2020
- Full Text
- View/download PDF
45. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
- Author
-
Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, and Karin M
- Subjects
- Antibodies, Monoclonal, Humanized pharmacology, B-Cell Activating Factor metabolism, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Cell Line, Tumor, Cell Survival drug effects, Cytoprotection drug effects, Gene Expression Regulation, Leukemic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Mechanistic Target of Rapamycin Complex 1 metabolism, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Prodrugs pharmacology, RNA, Messenger genetics, RNA, Messenger metabolism, Reactive Oxygen Species metabolism, Sulfonamides pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, NF-E2-Related Factor 2 metabolism, NF-kappa B metabolism, Receptor Tyrosine Kinase-like Orphan Receptors metabolism, Sequestosome-1 Protein metabolism, Signal Transduction drug effects
- Abstract
Progression of chronic lymphocytic leukemia (CLL) and resistance to therapy are affected by tumor microenvironmental factors. One such factor is B-cell activating factor (BAFF), a cytokine that is produced mainly by nurse-like cells (NLC) and enhances CLL cells survival and modulates response to therapy. In CLL cells, BAFF activates NF-κB signaling, but how NF-κB supports CLL survival is not entirely clear. In this study we show that BAFF induces accumulation of the signaling and autophagy adaptor p62/SQSTM1 in a manner dependent on NF-κB activation. p62 potentiates mTORC1 signaling and activates NRF2, the master regulator of the anti-oxidant response. We found that expression of NRF2 target genes, such as NAD(P)H quinone oxidoreductase 1 (NQO1), is particularly enriched in CLL cells with high ROR1 surface expression (ROR1
Hi ). ROR1Hi CLL cells with elevated NQO1 expression exhibit resistance to drugs that induce ROS accumulation, such venetoclax. However, such cells are more sensitive to compound 29h, a pro-drug that only becomes active after being metabolized by NQO1. Accordingly, 29h sensitizes high NQO1 CLL cells to venetoclax. Collectively, our study unravels a previously unknown signaling network through which the NF-κB-p62-NRF2 axis protects ROR1-high CLL cells from ROS-inducing therapeutics.- Published
- 2020
- Full Text
- View/download PDF
46. Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity.
- Author
-
Antonucci L, Porcu C, Timperi E, Santini SJ, Iannucci G, and Balsano C
- Subjects
- Blood Circulation, Cohort Studies, Disease Progression, Female, Humans, Immune Tolerance, Lymphocyte Activation, Male, Middle Aged, Neutrophil Activation, Severity of Illness Index, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Neutrophils immunology, Non-alcoholic Fatty Liver Disease immunology
- Abstract
Neutrophils or PolyMorphonuclear Neutrophils (PMNs) are key effector cells of the innate immune system and thanks to their remarkable plasticity, establish a cross talk with T cells modulating their survival and effector functions. During Nonalcoholic Steatohepatitis (NASH), the advanced form of hepatic steatosis or NAFL, PMNs infiltrate liver tissue, becoming a histological feature of NASH. Our aim was to evaluate the frequency of PMNs in NAFL and NASH patients in order to understand how they modulate the activity of circulating CD4
+ and CD8+ T cells. In our cohort of patients, NASH patients displayed a higher frequency of circulating PMNs that was strongly correlated to liver enzymes, grade of steatosis, inflammation and fibrosis, the hepatocellular ballooning, and NAFLD Activity Score (NAS). Furthermore, even if ex vivo , in both groups of patients, PMNs shared the same phenotype of resting cells, after 24 hours of coculture with autologous CD4+ and CD8+ T cells, PMNs of NASH patients acquired a more active phenotype, becoming able to strongly inhibit proliferation and activation of CD4+ and CD8+ T cells. The higher ability of PMNs of NASH patients in suppressing CD4+ and CD8+ T cells, over time, might contribute in reducing the immunological defense of liver tissue against damages thus taking part in the progression of the NAFL disease toward NASH., Competing Interests: The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Laura Antonucci et al.)- Published
- 2020
- Full Text
- View/download PDF
47. NRF2 as a regulator of cell metabolism and inflammation in cancer.
- Author
-
He F, Antonucci L, and Karin M
- Subjects
- Animals, Humans, Inflammation immunology, Inflammation metabolism, Inflammation pathology, Neoplasms metabolism, Neoplasms pathology, Inflammation complications, NF-E2-Related Factor 2 metabolism, Neoplasms etiology
- Abstract
Nuclear factor erythroid 2-related factor 2 (NRF2) is a master transcriptional regulator of genes whose products defend our cells for toxic and oxidative insults. Although NRF2 activation may reduce cancer risk by suppressing oxidative stress and tumor-promoting inflammation, many cancers exhibit elevated NRF2 activity either due to mutations that disrupt the negative control of NRF2 activity or other factors. Importantly, NRF2 activation is associated with poor prognosis and NRF2 has turned out to be a key activator of cancer-supportive anabolic metabolism. In this review, we summarize the diverse roles played by NRF2 in cancer focusing on metabolic reprogramming and tumor-promoting inflammation., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
48. Electronic measurement of femtosecond time delays for arbitrary-detuning asynchronous optical sampling.
- Author
-
Antonucci L, Solinas X, Bonvalet A, and Joffre M
- Abstract
Arbitrary-Detuning ASynchronous OPtical Sampling (ADASOPS) is a pump-probe technique which relies on the stability of femtosecond oscillators. It provides access to a multiscale time window ranging up to millisecond, combined with a sub-picosecond time resolution. In contrast with the first ADASOPS demonstration based on the interferometric detection of coincidences between optical pulses, we show here that the optical setup can now be reduced to a mere pair of photodetectors embedded in a specially-designed electronic system. In analogy with super-resolution methods used in optical microscopy for localizing single emitters beyond the diffraction limit, we demonstrate that purely electronic means allow the determination of time delays between each pump-probe pulse pair with a standard deviation as small as 200 fs. The new method is shown to be simpler, more versatile and more accurate than the coincidence-based approach.
- Published
- 2020
- Full Text
- View/download PDF
49. NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly.
- Author
-
He F, Antonucci L, Yamachika S, Zhang Z, Taniguchi K, Umemura A, Hatzivassiliou G, Roose-Girma M, Reina-Campos M, Duran A, Diaz-Meco MT, Moscat J, Sun B, and Karin M
- Subjects
- Adult, Animals, Autophagy genetics, Disease Models, Animal, ErbB Receptors genetics, Female, Hemangioma metabolism, Hemangioma pathology, Hepatic Veno-Occlusive Disease pathology, Hepatitis, Autoimmune pathology, Hepatomegaly genetics, Hepatomegaly pathology, Humans, Liver Neoplasms metabolism, Liver Neoplasms pathology, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Middle Aged, NF-E2-Related Factor 2 genetics, Oxidative Stress genetics, Receptor, Platelet-Derived Growth Factor alpha metabolism, Signal Transduction genetics, ErbB Receptors metabolism, Genes, erbB-1, Hepatic Veno-Occlusive Disease complications, Hepatic Veno-Occlusive Disease metabolism, Hepatitis, Autoimmune complications, Hepatitis, Autoimmune metabolism, Hepatomegaly complications, Hepatomegaly metabolism, NF-E2-Related Factor 2 metabolism, Proto-Oncogene Proteins c-akt metabolism
- Abstract
Background & Aims: Hepatomegaly can be triggered by insulin and insulin-unrelated etiologies. Insulin acts via AKT, but how other challenges cause hepatomegaly is unknown., Methods: Since many hepatomegaly-inducing toxicants and stressors activate NRF2, we examined the effect of NRF2 activation on liver size and metabolism using a conditional allele encoding a constitutively active NRF2 variant to generate Nrf2
Act-hep mice in which NRF2 is selectively activated in hepatocytes. We also used adenoviruses encoding variants of the autophagy adaptor p62/SQSTM1, which activates liver NRF2, as well as liver-specific ATG7-deficient mice (Atg7Δhep ) and liver specimens from patients with hepatic sinusoidal obstruction syndrome (HSOS) and autoimmune hepatitis (AIH). RNA sequencing and cell signaling analyses were used to determine cellular consequences of NRF2 activation and diverse histological analyses were used to study effects of the different manipulations on liver and systemic pathophysiology., Results: Hepatocyte-specific NRF2 activation, due to p62 accumulation or inhibition of KEAP1 binding, led to hepatomegaly associated with enhanced glycogenosis, steatosis and G2/M cell cycle arrest, fostering hyperplasia without cell division. Surprisingly, all manipulations that led to NRF2 activation also activated AKT, whose inhibition blocked NRF2-induced hepatomegaly and glycogenosis, but not NRF2-dependent antioxidant gene induction. AKT activation was linked to NRF2-mediated transcriptional induction of PDGF and EGF receptor ligands that signaled through their cognate receptors in an autocrine manner. Insulin and insulin-like growth factors were not involved. The NRF2-AKT signaling axis was also activated in human HSOS- and AIH-related hepatomegaly., Conclusions: NRF2, a transcription factor readily activated by xenobiotics, oxidative stress and autophagy disruptors, may be a common mediator of hepatomegaly; its effects on hepatic metabolism can be reversed by AKT/tyrosine kinase inhibitors., Lay Summary: Hepatomegaly can be triggered by numerous etiological factors, including infections, liver cancer, metabolic disturbances, toxicant exposure, as well as alcohol abuse or drug-induced hepatitis. This study identified the oxidative stress response transcription factor NRF2 as a common mediator of hepatomegaly. NRF2 activation results in elevated expression of several growth factors. These growth factors are made by hepatocytes and activate their receptors in an autocrine fashion to stimulate the accumulation of glycogen and lipids that lead to hepatocyte and liver enlargement. The protein kinase AKT plays a key role in this process and its inhibition leads to reversal of hepatomegaly., Competing Interests: Conflict of interest G.H and M.G. are full time employees of Genentech/Roche and hold company shares. Remaining authors declare no competing interests. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2020. Published by Elsevier B.V.)- Published
- 2020
- Full Text
- View/download PDF
50. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
- Author
-
Polito VA, Cristantielli R, Weber G, Del Bufalo F, Belardinilli T, Arnone CM, Petretto A, Antonucci L, Giorda E, Tumino N, Pitisci A, De Angelis B, Quintarelli C, Locatelli F, and Caruana I
- Subjects
- Animals, Humans, K562 Cells, Lymphocyte Activation genetics, Mice, Neoplasms, Experimental genetics, Neoplasms, Experimental therapy, Receptors, Antigen, T-Cell, gamma-delta genetics, Xenograft Model Antitumor Assays, Adoptive Transfer, Immunologic Memory, Lymphocyte Activation immunology, Neoplasms, Experimental immunology, Receptors, Antigen, T-Cell, gamma-delta immunology, T-Lymphocytes immunology, T-Lymphocytes transplantation
- Abstract
In the last years, important progresses have been registered in the treatment of patients suffering from oncological/haematological malignancies, but more still needs to be done to reduce toxicity and side effects, improve outcome and offer new strategies for relapsed or refractory disease. A remarkable part of these clinical benefits is due to advances in immunotherapy. Here, we investigate the generation of a novel, universal and ready-to-use immunotherapeutic product based on γδ-T lymphocytes. These cells are part of the innate immune system, exerting potent natural cytotoxicity against bacteria, viruses and tumours. This ability, coupled with their negligible alloreactivity, makes them attractive for adoptive immunotherapy approaches. To achieve a cell product suitable for clinical use, we developed a strategy capable to generate polyclonal γδ-T cells with predominant memory-Vδ1 phenotype in good manufacturing practice (GMP) procedures with the additional possibility of gene-modification to improve their anti-tumour activity. Irradiated, engineered artificial antigen-presenting cells (aAPCs) expressing CD86/41BBL/CD40L and the cytomegalovirus (CMV)-antigen-pp65 were used. The presence of CMV-pp65 and CD40L proved to be crucial for expansion of the memory-Vδ1 subpopulation. To allow clinical translation and guarantee patient safety, aAPCs were stably transduced with an inducible suicide gene. Expanded γδ-T cells showed high expression of activation and memory markers, without signs of exhaustion; they maintained polyclonality and potent anti-tumour activity both in vitro (against immortalised and primary blasts) and in in vivo studies without displaying alloreactivity signals. The molecular characterisation (phophoproteomic and gene-expression) of these cell products underlines their unique properties. These cells can further be armed with chimeric antigen receptors (CAR) to improve anti-tumour capacity and persistence. We demonstrate the feasibility of establishing an allogeneic third-party, off-the-shelf and ready-to-use, γδ-T-cell bank. These γδ-T cells may represent an attractive therapeutic option endowed with broad clinical applications, including treatment of viral infections in highly immunocompromised patients, treatment of aggressive malignancies refractory to conventional approaches, bridging therapy to more targeted immunotherapeutic approaches and, ultimately, an innovative platform for the development of off-the-shelf CAR-T-cell products., (Copyright © 2019 Polito, Cristantielli, Weber, Del Bufalo, Belardinilli, Arnone, Petretto, Antonucci, Giorda, Tumino, Pitisci, De Angelis, Quintarelli, Locatelli and Caruana.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.